- Published on
Medicine – Haemophilia B (Christmas Disease)
Haemophilia B, also known as Christmas disease, is an inherited bleeding disorder caused by deficiency or dysfunction of coagulation factor IX (FIX).
It is clinically almost indistinguishable from haemophilia A, which is caused by factor VIII deficiency.
Haemophilia B causes defective secondary haemostasis, leading to recurrent joint bleeding, deep muscle haematomas and prolonged bleeding following trauma or surgery.
1. Aetiology and Genetics
- Deficient factor: Factor IX.
- Gene: F9 gene on the X chromosome (Xq27).
- Inheritance: X-linked recessive.
- Affected individuals: Predominantly males, although females may also have symptomatic haemophilia.
- Alternative name: Christmas disease.
- Frequency: Less common than haemophilia A.
The name Christmas disease originated from the surname of the first patient described with this condition.
2. Pathophysiology
Factor IX is a vitamin K-dependent coagulation factor involved in the intrinsic coagulation pathway.
Activated factor IX (FIXa), together with activated factor VIII (FVIIIa), forms the intrinsic tenase complex, which activates factor X.
Factor IX deficiency therefore reduces factor X activation, thrombin generation and fibrin clot formation.
Illustration: Pathophysiology of Haemophilia B
3. Clinical Features
Haemophilia B behaves clinically like haemophilia A. Bleeding severity is closely related to residual factor IX activity.
A. Joint Bleeding (Haemarthrosis)
- Commonly affects the knees, ankles and elbows.
- Causes joint pain, swelling, warmth and reduced movement.
- Repeated haemarthroses may result in chronic haemophilic arthropathy.
B. Deep Muscle Bleeding
- Muscle haematomas.
- Iliopsoas haemorrhage.
- Possible nerve compression and compartment syndrome.
C. Other Bleeding Manifestations
- Prolonged bleeding following trauma.
- Excessive bleeding after surgery or dental extraction.
- Spontaneous bleeding in severe disease.
- Intracranial haemorrhage, a potentially life-threatening complication.
4. Classification According to Severity
| Severity | Factor IX Activity | Clinical Presentation |
|---|---|---|
| Severe | <1% | Frequent spontaneous joint and muscle bleeding |
| Moderate | 1–5% | Bleeding after minor trauma; occasional spontaneous bleeding |
| Mild | >5% to <40% | Bleeding mainly after significant trauma, surgery or procedures |
Severity is classified according to baseline factor IX activity, although bleeding patterns may vary between patients.
5. Laboratory Findings
| Investigation | Typical Result |
|---|---|
| Prothrombin time (PT) | Normal |
| Activated partial thromboplastin time (aPTT) | Often prolonged |
| Thrombin time (TT) | Normal |
| Platelet count | Normal |
| Fibrinogen | Normal |
| Factor IX activity | Reduced |
| Factor VIII activity | Usually normal |
6. Diagnosis
- Clinical history of recurrent joint or deep tissue bleeding.
- Family history suggestive of X-linked inheritance.
- Coagulation screening tests, particularly PT and aPTT.
- Specific factor IX activity assay to confirm the deficiency and determine severity.
- Genetic testing of the F9 gene when indicated.
A mixing study may help distinguish factor deficiency from a coagulation inhibitor when the aPTT is prolonged.
Diagnostic Flowchart
7. Treatment of Haemophilia B
A. Factor IX Replacement
Factor IX concentrate is a principal treatment for haemophilia B.
It is used for acute bleeding, perioperative haemostatic cover and prophylaxis.
Extended-half-life factor IX products may reduce the frequency of prophylactic infusions.
B. Prophylaxis
Regular prophylaxis is recommended for many patients with severe haemophilia to prevent recurrent joint bleeding and long-term arthropathy.
C. Additional Management
- Tranexamic acid for selected mucosal bleeding episodes.
- Physiotherapy and joint protection.
- Avoidance of unnecessary intramuscular injections.
- Avoidance of medications that impair platelet function unless specifically indicated.
- Specialist management of factor IX inhibitors if they develop.
- Gene therapy or other newer therapies may be considered in selected patients according to eligibility and local availability.
8. Haemophilia A Versus Haemophilia B
| Feature | Haemophilia A | Haemophilia B |
|---|---|---|
| Deficient factor | Factor VIII | Factor IX |
| Alternative name | Classical haemophilia | Christmas disease |
| Inheritance | X-linked recessive | X-linked recessive |
| Clinical features | Joint and muscle bleeding | Joint and muscle bleeding |
| PT | Normal | Normal |
| aPTT | Often prolonged | Often prolonged |
| Platelet count | Normal | Normal |
| Specific diagnosis | Reduced factor VIII activity | Reduced factor IX activity |
| Main replacement therapy | Factor VIII | Factor IX |
| DDAVP | May help selected mild cases | Ineffective |
9. High-Yield Examination Summary
| Aspect | Important Point |
|---|---|
| Alternative name | Christmas disease |
| Deficient factor | Factor IX |
| Gene | F9 gene on X chromosome |
| Inheritance | X-linked recessive |
| Pathophysiology | Impaired intrinsic tenase activity and reduced thrombin generation |
| Clinical presentation | Haemarthrosis, muscle haematomas and prolonged bleeding |
| PT | Normal |
| aPTT | Often prolonged |
| Diagnosis | Reduced factor IX activity |
| Treatment | Factor IX replacement and prophylaxis when indicated |
10. Key Examination Pearls
- Haemophilia B is also known as Christmas disease.
- It results from factor IX deficiency.
- It is inherited in an X-linked recessive pattern.
- Factor IX is a vitamin K-dependent coagulation factor.
- Haemophilia B is clinically similar to haemophilia A.
- Haemarthrosis and deep muscle bleeding are characteristic manifestations.
- PT and platelet count are normal, while aPTT is often prolonged.
- Mild disease may have a normal aPTT.
- Diagnosis is confirmed by reduced factor IX activity.
- Treatment primarily involves factor IX replacement.
- Desmopressin is ineffective in haemophilia B.
Haemophilia A and B have virtually identical clinical presentations and routine coagulation screening patterns. They are distinguished by specific factor assays: factor VIII deficiency in haemophilia A and factor IX deficiency in haemophilia B.
Suspected serious bleeding, particularly intracranial, neck, abdominal or iliopsoas haemorrhage, requires urgent haemophilia specialist assessment and prompt haemostatic treatment. Management must be individualised according to disease severity, inhibitor status and available therapies.
Kembara Xtra – Medicine Revision Notes